<DOC>
	<DOCNO>NCT00717509</DOCNO>
	<brief_summary>We go investigate association multiple genetic polymorphism metabolic side effect patient schizophrenia take clozapine .</brief_summary>
	<brief_title>Association Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change Schizophrenia</brief_title>
	<detailed_description>The use antipsychotic , especially clozapine olanzapine associate metabolic side effect , put patient schizophrenia risk cardiovascular morbidity diabetes . The prevalence metabolic syndrome 53.8 % patient take clozapine . The high interindividual variability antipsychotic-induced metabolic abnormality suggest genetic makeup possible determinant . The genotype multiple gene HTR2C , LEP , adrenergic receptor , PPAR , GNB3 suggest association metabolic side effect ( weight , glucose , lipid , BP , metabolic syndrome ) patient use antipsychotic . We go investigate whether multiple genetic polymorphism associate metabolic side effect patient take clozapine .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>age 1865 understand sign inform consent refuse participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>metabolic side effect</keyword>
	<keyword>clozapine</keyword>
	<keyword>genetic polymorphism</keyword>
</DOC>